PestleMedicine Explained

Methenamine hippurate

This is a urinary tract anti-bacterial medicine used to prevent repeated urinary tract infections. It is also used during urinary examinations and treatments to reduce the risk of infection, and in people who have a urinary catheter for a long time.

Active ingredient: Methenamine hippurate

Official leaflet

Key facts

  1. Used to prevent urinary tract infections that keep coming back, not to treat an infection you already have.
  2. Adults usually take 1 tablet twice a day; the dose may be raised to 1 tablet three times a day if you have a catheter.
  3. Do not use it if you have kidney or liver problems, gout, severe dehydration, metabolic acidosis or a kidney infection.
  4. Tell the doctor or nurse you are using it if you give a urine sample, as it can give misleading results for some substances.
  5. It can be taken with or without food and drink.

Who should not take methenamine hippurate

The leaflet says not to take it if any of these apply to you.

  • if you are allergic to methenamine hippurate or any of the other ingredients
  • if you are hypersensitive to formalin
  • if you suffer from renal impairment, are severely dehydrated or have gout
  • if you suffer from liver impairment
  • if you have metabolic acidosis (a high amount of acidic substances in the body, which causes symptoms such as increased heart rate, headache and nausea)
  • if you have a kidney infection

How to take methenamine hippurate

  • Adults: 1 tablet twice a day. If you have a catheter the dose may be increased to 1 tablet three times a day.
  • Children 6 to 12 years: half a tablet twice daily. Children older than 12 years: 1 tablet twice daily.
  • The tablet can be divided into two equal doses. Tablets may be halved or crushed and taken with water if you cannot swallow them whole.
  • Can be taken with or without food and drink.
  • If you forget a dose, take your next dose as planned and do not take a double dose.

Side effects

How common each side effect is

Grouped the way the leaflet groups them. Most people get none, or only a few. Each figure is the most that are affected, so "up to 1 in 10" can mean far fewer.

Common

Up to 1 in 10 people

  • nausea
  • vomiting
  • rashes
  • irritation of the bladder

Rare

Up to 1 in 1,000 people

  • blood in the urine

Not known

The leaflet says how often is not known

  • diarrhoea
  • abdominal pains
  • pruritus

If you get a side effect, you can report it to the regulator through the Yellow Card scheme.

Pregnancy and breastfeeding

No known risks when used during pregnancy, but ask your doctor before using it if you are pregnant, think you may be pregnant or are planning a baby. Methenamine hippurate passes into breast milk but is not likely to affect the child; discuss with your doctor if you need more than temporary use while breast-feeding.

Taking it with other medicines

The leaflet says to tell your doctor or pharmacist if you take any of these. This list is not checked against the medicines you take.

  • Medicines used for heartburn, as these decrease the effect of Methenamine Tablets by making your urine less acidic
  • Sulphonamides (also known as sulpha medicines), which may contribute to crystals forming in the urine (crystalluria) and possibly lead to kidney problems

Where this comes from

Everything on this page is taken from one official document: the patient information leaflet that the UK medicines regulator (MHRA) approved for this product. Pestle reorganises it and puts it in plainer words. It adds nothing from anywhere else and does not rate medicines.

Product
Methenamine Hippurate 1g Tablets
Product licence
PL 12762/0552
Leaflet dated
Checked against the leaflet
Automated check
8 of 8 side effects matched to the wording of the leaflet

Other makers of methenamine hippurate publish their own leaflets, which can differ slightly. Always read the leaflet that came with your medicine.

Read the official leaflet Original on the MHRA site How we make these pages

The same facts for software and AI agents: JSON · Markdown.